iQ&A Interactive Medical Intelligence Zone for PE and DVT
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor.
The iQ&A platform stresses:
  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period August 22, 2013 through August 22, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 115 segments, totaling 4:17, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

4.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of pulmonary embolism and deep vein thrombosis.

Release Date

August 22, 2013

Expiration Date

August 22, 2015

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with familial hypercholesterolemia.

This constituency of HCPs shall include the following audience:

  • Cardiologists
  • Thrombosis medicine specialists
  • Neurologists
  • Preventive medicine specialists
  • Cardiology department program directors
  • Clinical geneticists
  • Clinical cardiovascular pharmacists
  • Related specialists

Registration

Participation in this iQ&A interactive Medical Intelligence Zone for PE and DVT is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an independent grant from Bayer Healthcare.

Bayer HealthCare

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure
Samuel Z. Goldhaber, MD
Program Chairman and Moderator

Professor of Medicine

Harvard Medical School

Director, VTE Research Group

Cardiovascular Division

Brigham and Women's Hospital

President, North American Thrombosis Forum (NATF)

Boston, Massachusetts

Consultant: Baxter, Boehringer Ingelheim, Bristol Myers Squibb,
Daiichi Sankyo, Eisai, Merck, Pfizer, Portola, Sanofi Aventis
Research Support: Daiichi Sankyo, Eisai, EKOS, J&J, Sanofi Aventis

Giancarlo Agnelli, MD
Professor of Internal Medicine
University of Perugia, Italy
Director of the Department of Internal and Cardiovascular Medicine and Stroke-Unit
University Hospital
Perugia, Italy

Speaker: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Sanofi

Professor Henri Bounameaux, MD
Professor of Medicine
Director of the Division of Angiology and Haemostasis
Chairman of the Department of Medicine
University Hospitals of Geneva
Geneva, Switzerland

Honoraria: Bayer-Schering Pharma, Pfizer
Advisory Board: Bayer-Schering Pharma, Pfizer
Research Support: Daiichi-Sankyo

Benjamin Brenner, MD
Professor of Hematology
Director Thrombosis and Hemostasis Unit
Rambam Medical Center
Israel Institute of Technology
Haifa, Israel

Grant/Research Support: sanofi-aventis


Mark Crowther, MD, MSc, FRCPC
Professor, Department of Medicine, Hematology and Thromboembolism and Pathology and Molecular Medicine
Leo Pharma Chair in Thromboembolism Research
McMaster University
Director of Laboratory Hematology
Hamilton Regional Laboratory Medicine Program
Chief of Laboratory Medicine
St Joseph’s Healthcare and Hamilton Health Sciences
Hamilton, Ontario
Canada

Nothing to disclose

James Douketis, MD
Professor, Division of Hematology and Thromboembolism
Department of Medicine
McMaster University
Associate Director
Clinical Teaching Unit
St. Joseph's Hospital
Hamilton, Ontario
Canada

Consultant/Advisory Board: Bayer; Astra-Zeneca; Biotie; Boehringer-Ingelheim; BMS; Medicines Company

John W. Eikelboom, MD

Associate Professor of Medicine

McMaster University

Canada Research Chair in Cardiovascular Medicine
Hamilton, Ontario
Canada

Speaker: AstraZeneca, Boehringer Ingelheim, and sanofi-aventis.

Professor Sylvia Haas, MD, PhD
Professor of Medicine

Technical University of Munich

Munich, Germany

Advisor or consultant: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Isis Pharmaceuticals, Inc.; Sanofi
Speaker’s Bureau: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company

Menno Huisman, MD, PhD
Associate Professor
Department of Medicine
Chairman, Section of Vascular Medicine
Leiden University Medical Center
Chairman, National Education Board of Vascular Medicine in The Netherlands
Leiden, The Netherlands

Grant/Research Support: AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, and Pfizer


Elaine M. Hylek, MD, MPH

Associate Professor of Medicine

Department of Medicine

Boston University Medical Center

Boston, Massachusetts

Consultant: Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Pfizer, Johnson & Johnson
Grant Research: Orbit AF Registry, Aristotle Trial
Executive Steering Committee: Orbit AF Registry, Aristotle Trial

Ajay Kakkar, MBBS, PhD, FRCS

Head of the Centre for Surgical Sciences

Barts and the London Queen Mary's School of Medicine and Dentistry

Thrombosis Research Institute

London, UK

Consultant: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi
Grant/Research Support: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi

Craig M. Kessler, MD
Professor, Departments of Medicine and Pathology
Georgetown University Medical School
Director, Comprehensive Hemophilia and Thrombosis Treatment Center
Georgetown University Medical Center
Washington, DC

Advisor or consultant: Baxter; Bayer Healthcare Pharmaceuticals; Grifols; Novo Nordisk; Octapharma; Pfizer Inc.
Grant/Research Support: Baxter; Bayer Healthcare Pharmaceuticals; Grifols; Novo Nordisk; Octapharma; Pfizer Inc.


Marcel Levi, MD PhD
Professor of Medicine
Dean Faculty of Medicine
University of Amsterdam
Amsterdam, the Netherlands

Nothing to disclose

Saskia Middeldorp, MD, PhD
Co-Chair, Vascular Medicine Center
Associate Professor
Department of Vascular Medicine
University of Amsterdam
Amsterdam, The Netherlands

Nothing to disclose


Paolo Prandoni, MD
Department of Medical and Surgical Sciences
2nd Chair of Internal Medicine
University of Padua School of Medicine
Padua, Italy

Nothing to disclose


Alexander G. G. Turpie, MD, FRCP, FACP, FACC, FRCPC

Professor of Medicine, Emeritus

Department of Medicine

Hamilton Health Sciences-General Hospital

Hamilton, Ontario
Canada

Consultant: Bayer Pharma, Janssen, Astellas, Takeda
Speaker’s Bureau: Janssen, Boehringer-Ingelheim

Jeffrey I. Weitz, MD FRCP, FACP

Professor of Medicine and Biochemistry

McMaster University

Canada Research Chair in Thrombosis

Heart and Stroke Foundation

J.F. Mustard Chair in Cardiovascular Research
Hamilton, Ontario
Canada

Advisor or consultant: Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Daiichi Sankyo, Inc.; Takeda Pharmaceuticals North America, Inc.; Bayer HealthCare Pharmaceuticals; Pfizer Inc.; Portola Pharmaceuticals, Inc.; Merck & Co., Inc.

 

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Better manage treatment of DVT and PE with non-monitored oral anticoagulants, with a focus on factor Xa inhibition;
  • Become more clinically proficient preventing stroke in patients with atrial fibrillation;
  • Understand the design, rationale, and results of clinical trials evaluating non-monitored oral anticoagulants for thrombosis management across the ateriovenous, morbidity continuum;
  • Identify and risk-stratify patients with DVT and PE who are eligible for outpatient therapy with non-monitored anticoagulants;
  • Assess dosing requirements, based on renal function, risk scores, and other clinical parameters of patients with thrombosis risk or acute thrombosis who are appropriate candidates for oral-based anticoagulation;
Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC